Last reviewed · How we verify
rhFSH+rhLH
rhFSH and rhLH are recombinant human gonadotropins that stimulate follicle development and ovulation in women undergoing fertility treatment.
rhFSH and rhLH are recombinant human gonadotropins that stimulate follicle development and ovulation in women undergoing fertility treatment. Used for Infertility in women undergoing assisted reproductive technology (ART), Anovulation and ovulatory disorders.
At a glance
| Generic name | rhFSH+rhLH |
|---|---|
| Sponsor | Fundación Santiago Dexeus Font |
| Drug class | Gonadotropin |
| Target | FSH receptor and LH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive/Fertility |
| Phase | FDA-approved |
Mechanism of action
Follicle-stimulating hormone (FSH) promotes the growth and maturation of ovarian follicles, while luteinizing hormone (LH) triggers the final maturation and ovulation of the egg. The combination of recombinant FSH and LH mimics the natural hormonal cascade required for successful ovulation in assisted reproductive technology cycles.
Approved indications
- Infertility in women undergoing assisted reproductive technology (ART)
- Anovulation and ovulatory disorders
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions
- Headache
- Abdominal pain/bloating
- Nausea
Key clinical trials
- PErsonalized Addition of Recombinant LH in Ovarian Stimulation (PHASE4)
- Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) (PHASE3)
- To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |